NeuroSigma.png
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
January 31, 2023 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...
NeuroSigma.png
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
October 17, 2022 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
NeuroSigma.png
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
September 27, 2022 12:00 ET | NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...
NeuroSigma.png
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
June 14, 2022 11:00 ET | NeuroSigma, Inc.
Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide Monarch eTNS Systems and funding for long-term follow-up ...
Signing Ceremony
NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
December 08, 2021 05:00 ET | NeuroSigma, Inc.
Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KTSignificant investment in NeuroSigma’s digital health and neuro-electronics platform ...